Off-label use of quetiapine in new zealand-a cause for concern?

New Zealand Medical Journal

Volumn 124, Issue 1336, 2011, Pages

  Glue, Paul ^a   Gale, Chris ^b  

^a Hazel Buckland Chair in Psychological Medicine   (New Zealand)

^b UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENERGIC RECEPTOR BLOCKING AGENT; ANTIDEPRESSANT AGENT; ANTIHISTAMINIC AGENT; BENZODIAZEPINE DERIVATIVE; BUSPIRONE; CLONIDINE; QUETIAPINE; ZOPICLONE; NEUROLEPTIC AGENT;

ANXIETY DISORDER; COHORT ANALYSIS; EDITORIAL; HUMAN; INSOMNIA; LOW DRUG DOSE; METABOLIC DISORDER; NEW ZEALAND; OFF LABEL DRUG USE; POSTTRAUMATIC STRESS DISORDER; PSYCHIATRIST; SEDATION; SIDE EFFECT; SUDDEN DEATH; TARDIVE DYSKINESIA; NOTE; STATISTICS;

ANTIPSYCHOTIC AGENTS; HUMANS; OFF-LABEL USE;

EID: 79958288522     PISSN: None     EISSN: 11758716     Source Type: Journal    
DOI: None     Document Type: Editorial

References (13)

1. Chouinard G. The search for new off-label indications for antidepressant, antianxiety, antipsychotic and anticonvulsant drugs. Focus. 2006;4:528-538.
2. Monasterio E, McKean A. Off-label use of atypical antipsychotic medications in Canterbury, New Zealand. N Z Med J. 2011;124(1336). http://www.nzma.org.nz/journal/124-1336/4700
3. Philip NS, Mello K, Carpenter LL, et al. Patterns of quetiapine use in psychiatric inpatients: an examination of off-label use. Ann Clin Psychiatry. 2008;20:15-20.
4. Ravindran AV, Al-Subaie A, Abraham G. Quetiapine: novel uses in the treatment of depressive and anxiety disorders. Expert Opin Investig Drugs. 2010;19:1187-204.
5. Glue P, Loan A, Gale C. New prospects for the drug treatment of Generalized Anxiety Disorder-a systematic review. Curr Drug Ther. 2010;5:86-94.
6. FDA Memorandum; Department of Health and Human Services Public Health Service, Food and Drug Administration; Center for Drug Evaluation and Research. http://www.fda.gov/ohrms/dockets/ac/09/briefing/2009-4424b2-01-FDA.pdf
7. Wiegand MH, Landry F, Brückner T, et al. Quetiapine in primary insomnia: a pilot study. Psychopharmacology (Berl). 2008;196:337-8.
8. Wine JN, Sanda C, Caballero J. Effects of quetiapine on sleep in nonpsychiatric and psychiatric conditions. Ann Pharmacother. 2009 Apr;43(4):707-13.
9. Cates ME, Jackson CW, Feldman JM, et al. Metabolic consequences of using low-dose quetiapine for insomnia in psychiatric patients. Community Ment Health J. 2009;45:251-4.
10. Ray WA, Chung CP, Murray KT, et al. Atypical antipsychotic drugs and the risk of sudden cardiac death. NEJM. 2009;360:225-35.
11. Kuehn BM. FDA panel issues mixed decision on quetiapine in depression and anxiety. JAMA. 2009;301:2081-2.
12. Fischer BA, Boggs DL. The role of antihistaminic effects in the misuse of quetiapine: a case report and review of the literature. Neurosci Biobehav Rev. 2010;34:555-8.
13. Medsafe. Regulatory Issues, Unapproved Use of Medicines. http://www.medsafe.govt.nz/profs/RIss/unapp.asp